Multiple Myeloma: Treatment is Getting Individualized

摘要: Multiple myeloma (MM) is a heterogeneous disease with varied outcome. The novel agents including two major classes of drugs; the immunomodulatory drugs and proteasome inhibitors unprecedented response rates, have replaced conventional chemotherapy. With monoclonal antibodies on horizon, outcome this disorder will further improve. Progression in risk stratification systems has made it possible to predict course as well patients categorization into low high risk. In addition, detection minimal residual by serum free light chain assay, flow cytometry, molecular techniques like polymerase reaction positron emission tomography scan playing an important role modifying treatment. An extensive research biology improved our knowledge regarding interplay between cells elements bone marrow microenvironment which contribute sustain proliferation survival de novo drug resistance. Again, insight genetic epigenetic interactions MM exposed new targets. All these opened gateway for therapeutic strategies focus based individualized therapy.